Loss of occludin leads to the progression of human breast cancer by Martin, Tracey Amanda et al.
Abstract. Occludin is an integral membrane protein localised
at tight junctions (TJs). It has become clear that the TJ is an
important structure that cancer cells must overcome in order
to metastasize successfully. The purpose of this study was to
elucidate the importance of the expression of occludin in
human breast cancer. Human tissues and breast cancer cell
lines were amplified for functional regions of occludin.
Tumour tissues showed truncated and/or variant signals.
There was also considerable variation in the expression of
occludin in the 10 human breast cancer cell lines investigated.
Western blotting demonstrated that variants in the MDA-
MB-231 and MCF-7 human breast cancer cell lines did not
fit the expected occludin signals for changes in phospho-
rylation status. Immunostaining showed similarly disparate
levels of expression. Ribozyme knockdown resulted in
increased invasion, reduced adhesion and significantly
reduced TJ functions. Q-RT-PCR analysis of 124 tumour and
33 background human breast tissues showed occludin to be
significantly decreased in patients with metastatic disease.
Immunohistochemical staining showed a decreased expression
of occludin in the tumour sections. This study demonstrates
for the first time that occludin is differentially expressed in
human breast tumour tissues and cell lines. This loss of or
aberrant expression has clear repercussions as to the
importance of occludin in maintaining TJ integrity in breast
tissues. Such inappropriate expression could play a part in
breast cancer development.
Introduction
Occludin was the first transmembrane tight junction (TJ)
protein to be identified (1,2). It bears 4 transmembrane
domains in its N-terminal half, with both the N- and C-
termini located in the cytoplasm, and the C-terminal (~150
amino acids) binding to ZO-1 (3,4). The cytoplasmic domain
(domain E) also interacts with both ZO-1 and -2. The
topology of occludin predicts 2 extracellular loops projecting
into the paracellular space which interacts with loops
originating from the occludin protein of the neighbouring cell
or unidentified molecules, to promote the interaction and
sealing of the paracellular space (5). The C-terminal of
occludin is sufficient to mediate endocytosis, as the C-
terminal governs the intracellular transport of occludin (6).
Occludin is a functional component of the TJ and is widely
expressed in both endothelial and epithelial cells, but not in
cells and tissues without TJs (7).
The extracellular surface of occludin has been found to be
directly involved in cell-cell adhesion and its ability to confer
adhesiveness is correlated with the ability to co-localise with
ZO-1 (8). The predicted size of occludin is 60-65 or 82 kDa.
The discrepancy in the size of occludin protein is a result of
differential serine and threonine phosphorylation. The larger
phosphorylated form of occludin is found localised within
the TJ whereas the smaller, less phosphorylated forms are
found in the basolateral membrane and cytosol (5,9). Thus,
its phosphorylation is directly related to its function. Small
differences in the electrophoretic mobility of occludin are
found to be distinct phosphorylated variants with altered
membrane localisation, indicating that the phosphorylation of
occludin is an important step in TJ assembly (9-11). In
endothelial cells, it has been shown that the selective proteo-
lytic cleavage of occludin by metalloproteinases after the
inhibition of protein tyrosine phosphatases, raises paracellular
permeability (12).
Cancer metastasis proceeds by a series of steps, among
which the capacity of cancer cells to invade surrounding
normal tissues is of central importance in the dissemination
of disease (13). The interaction between cancer and meso-
thelial cells lining the cavity is crucial for achieving the
complex sequence of cancer cell dissemination into the body
cavity. In the process of the submesothelial invasion of
cancer cells, the TJs of the mesothelial cells can function as a
defence against the invasion of cancer cells. Likewise, TJs
are also a defense barrier against endothelial invasion (both
in intravasation and extravasation), as they are known to
work as a barrier to the paracellular passage of cells and
substances between the epithelial or endothelial cells (13).
Metastasis is the primary cause of fatality in breast cancer
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patients. Although there are believed to be numerous events
contributing to the process of metastasis, it is widely accepted
that the loss of cell-cell adhesion in the neoplastic epithelium
is necessary for the invasion of the surrounding stromal
elements and subsequent metastatic events (14).
Early studies have demonstrated a correlation between the
reduction of TJs and tumour differentiation, with experimental
evidence emerging to place TJs in the frontline as the structure
that cancer cells must overcome in order to metastasize
(15-18). Although there have been a considerable number of
studies on TJs and their role in a number of diseases, it was
not till later that their possible role in tumourigenesis was
studied. To date most of the studies have concentrated on cell
lines, and to a limited degree on colorectal and pancreatic
cancers, with only a few studies being carried out on breast
cancer concentrating on claudin-1 (SEMP-1), claudin-7, and
ZO-1 and -2 expression (14,18-24).
Our previous study demonstrated that the plaque proteins
(ZO-1, -2, -3 and MUPP-1) have an altered expression in
human breast cancer (24) and that the human breast cancer
cell TJ formation can be modulated by a number of factors
(24,25). The present study aims to shed light on the way that
occludin is expressed in both human breast cancer cell lines
and human breast cancer.
Here, we will show that occludin is expressed in variant
forms in human breast cancer cell lines and in human breast
cancer. We will further demonstrate that the loss of occludin
expression after knockdown, results in breast cancer cell
lines with a significantly altered phenotype and reduced TJ
functionality. We will also illustrate that occludin is lost in
human breast cancer tissues and is associated with patient
prognosis.
Materials and methods
Reagents and antibodies. Anti-occludin (N-19, sc-8145 and
H-279 epitope, sc-5562) and actin (sc-8432) antibodies were
purchased from Pharmingen International (San Diego, CA,
USA). Anti-occludin (C-terminal epitope, 71:1,500) antibody
was purchased from Zymed (Invitrogen Ltd., Paisley, UK).
Peroxidase-conjugated anti-mouse and anti-rabbit IgG for
Western blotting were from Sigma-Aldrich Ltd. (Poole, UK).
FITC- or TRITC-conjugated anti-mouse, anti-goat and anti-
rabbit IgG were from Sigma-Aldrich. FITC-conjugated
dextran (40 kDa) was obtained from Molecular Probe Inc.
(Eugene, OR, USA). Carbonate filter inserts with a pore size
of 0.4 μm (for 24 well-plates) were from Greiner Bio-One
Ltd. (Stonehouse, Glos, UK). Gold electrode arrays (8W10E)
were purchased from Applied Biophysics Inc. (Troy, NY,
USA).
Cell lines. The human breast cancer cell lines MDA-MB-
231, MCF-10A, BT487, BT549, BT474-KC, MDA-MB-436,
MDA-MB-548, MDA MB-435s, ZR751 and MCF-7, were
from the American Type Culture Collection (ATCC;
Rockville, MD, USA) and the human fibroblast cell line,
MRC5, was from the European Collection of Animal Cell
Cultures (ECACC, Wiltshire, UK). The human vascular
endothelial cell, HECV, was from the Interlab Cell Line
Collection (ICLC; Naples, Italy). The cells were routinely
maintained in Dulbecco's Modified Eagle's medium (Sigma-
Aldrich) supplemented with 10% fetal calf serum, penicillin
and streptomycin (Sigma-Aldrich).
Conventional PCR. Conventional PCR mix (ABgene, Epsom,
Surrey, UK) was used to screen the transcript expression of a
number of TJ constituent molecules in human breast cancer
cell lines and mammary tissues, with selected control cells.
Normal human endothelial cells were used as the positive
control. Cycling conditions were as follows: Enzyme acti-
vation at 95˚C for 5 min, 1 cycle, followed by 36 cycles of
denaturing at 95˚C for 15 sec, annealing at 55˚C for 15 sec,
and then extension at 72˚C for 2 min. The amplified products
were visualised on agarose gels.
Screening of aberrant occludin forms. Tissues and breast
cancer cells lines were amplified for functional regions of
occludin (Fig. 1). The primer pair Oc1F and Oc1R was
designed to span the N-terminus (expected size 616 bp)
OC1F ATGTCATCCAGGCCTC and OC1R ATACACAAT
TGTGGCA. The primer pair Oc3F and Oc3R was designed
to span the first transmembrane loop (expected size 515 bp)
OC3F GCATCATGGTGTTTATTGC and OC3R GAAGCT
CCTGAACCACTTA. The primer pair Oc4F and Oc4R was
designed to span the C-terminus (expected size 500 bp)
OC4F GGTTTTATCCAGAGTCTTCCT and OC4R TTGA
TGTGTGAACAATTTGCT. Screening was carried out using
conventional PCR: Enzyme activation at 95˚C for 5 min, 1
cycle, followed by 36 cycles of denaturing at 95˚C for 30 sec,
annealing at 55˚C for 30 sec, and then extension at 72˚C for
1 min. The amplified products were visualized on agarose
gels. Six paired normal and breast cancer tissues and 10
breast cancer cell lines were assessed to determine the
aberrant forms of occludin. In addition, primers were also
designed to amplify the full occludin molecule (expected size
1516 bp) as follows: OCCcodeF1 ATGTCATCCAGGC
CTCTT and OCCcodeR1 TCTGTCTATCATAGTCTCCA
ACC: Cycling conditions were as follows: Enzyme activation
at 95˚C for 5 min, 1 cycle, followed by 36 cycles of
denaturing at 95˚C for 30 sec, annealing at 55˚C for 30 sec,
and then extension at 72˚C for 2 min. The amplified products
were visualised on agarose gels.
MARTIN et al:  OCCLUDIN AND BREAST CANCER PROGRESSION724
Figure 1. Schematic illustrating the different regions and putative functions
of the occludin protein.
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Evaluation of occludin promotor hypermethylation. Genomic
DNA from multiple sections from frozen tissue and human
breast cancer cells was extracted using standard DNA
extraction protocol. Methylation-specific PCR was carried out
as described previously (26). DNA (1 μg) was denatured in
NaOH (to a final concentration of 0.2 M) for 10 min at 37˚C,
followed by 10 mM of freshly prepared hydroquinone and 3 M
sodium bisulfite (at pH 5.0). Following incubation at 50˚C
for 16 h, the DNA was purified using the Wizard DNA purifi-
cation kit (Promega) and standard ethanol precipitation.
Hypermethylation was analysed by PCR using the following
primers: OCCUMF TACAACACCCAAAACTAAAATACT
TTTTCA and OCCUMR TATTTTAGGGTTTTTTTTTGTT
TATTTGGTTT for the unmethylated promoters and OCCMF
CAACACCCGAAACTAAAATACTTTTC and OCCMR
TTTTAGGGTTTTTTTTTGTTTATTCGGTTC for the
methylated promoters. Methylation-specific-PCR conditions
were as follows: Enzyme activation at 95˚C for 5 min, 1 cycle,
followed by 36 cycles of denaturing at 95˚C for 15 sec,
annealing at 58˚C for 15 sec, and then extension at 72˚C for
30 sec. The PCR products were separated on standard 10%
PAGE gels.
Construction of the occludin ribozyme for knockdown experi-
ments. The ribozyme transgene to occludin was constructed
as previously reported (28). The following DNA oligos were
used to generate the ribozymes: OCCrib1F CTGCAGGC
TGGCTGAGAGAGCATTGGTCCTGATGAGTCCGTGAG
GA and OCCrib1R ACTAGTGGAGAGATGCATGTTTTC
GTCCTCACGGACT. The ribozyme gene cassettes were
cloned into the pEF/V5-His TOPO® TA parent vector
(Invitrogen). The vectors were transfected into chemically
competent Escherichia coli, and bacterial colonies were
grown on agar plates. The colonies were examined using the
PCR technique to confirm the absence of occludin expression.
Plasmid purification and extraction was performed using a
plasmid extraction kit (Qiafilter; Qiagen, Crawley, UK). The
concentration of each plasmid was determined using a spectro-
photometer (WPA UV 1101; Biotech Photometer, Cambridge,
UK). MDA MB-231 human breast cancer cells (100 μl) were
mixed with 10 μl of occludin or the control plasmid for 2 min
and were then electroporated at 170 V with an electroporator
(Easyjet; Flowgen). The cells were immediately transferred
to complete medium pre-warmed to 37˚C and plated into 6
well-plates. After 24 h the cells were transferred to 25 ml
cell culture flasks and selected using blasticidin at 5 μg/ml.
The medium was changed every 3-4 days. After 4 weeks, the
cells were transferred to maintenance medium (with 1 μg/ml
blasticidin). The occludin knockdown cells were designated
as MDA MB-231ΔOcc and MCF-7ΔOcc, the wild-type cells
MDA MB-231WT and MCF-7WT and the control plasmid cells
MDA MB-231Plas and MCF-7Plas. Stably transfected cells
were then used for subsequent assays (after 6 weeks of
culture and confirmation of expression).
In vitro biological assays analyzing occludin knockdown
cells. Six assays were used to determine what, if any, the effect
of occludin knockdown would have on the human breast
cancer cell lines, MDA-MB-231 and MCF-7. Recombinant
human HGF was used as a stimulator of invasive behaviour.
Trans-epithelial resistance (TER). TER was measured with
an EVOM Voltohmmeter (EVOL; World Precision Instru-
ments, Aston, Herts, UK), equipped with a pair of STX-2
chopstick electrodes (WPI, Sarasota, FL, USA), as we have
previously reported (23,25). Briefly, the cells were seeded
into the 0.4 μm pore size insert (Greiner Bio-One) and
allowed to reach full confluence, after which fresh medium
was replaced for further experiments. Inserts without cells,
inserts with cells in medium and inserts with cells with HGF
(25 ng/ml) were tested for a period of 2 h. Electrodes were
placed at the upper and lower chambers and resistance was
measured with the voltometer.
Trans-epithelial cell permeability. This was determined using
fluorescently labelled dextran FITC-Dextran 40 (Sigma-
Aldrich), the molecular weight being 40 kDa (23,25). Human
breast cancer cells were prepared and treated as described
above, but with the addition of Dextran-40 to the upper
chamber. Medium from the lower chamber was collected for
intervals up to 2 h after the addition of HGF. The relative
fluorescence from these collections was read on a multi-
channel fluorescence reader (Denly, Sussex, UK).
Invasion assay. The invasiveness of the MDA-MB-231 breast
cancer cell line was assessed using the following in vitro
assay. Transwell chambers equipped with 6.5 mm diameter
polycarbonate filters (pore size 8 μm) (Becton-Dickinson
Labware, Oxford, UK) were pre-coated with 50 μg/
membrane of solubilised basement membrane in the form of
Matrigel (Collaborative Research Products, Bedford, MA,
USA). After membrane re-hydration, 15,000 cells were
aliquoted into each insert with/without HGF. After 96-h co-
culture, the non-invasive cells were removed with cotton
swabs. The invaded cells on the underside of the insert were
fixed and stained with crystal violet, followed by micro-
scopic counting (20 fields/insert).
Cell matrix adhesion assay. The cell-matrix attachment assay
was carried out as previously reported (27). Briefly, Matrigel
(10 μg/well) was added to 96-well plates, which were
incubated for 24 h to allow the binding of the matrix protein to
the surface of the well. The plates were then washed and
blocked with 5% bovine serum albumin (Sigma-Aldrich).
The cells were added at 104/well for 30 min, followed by
aspiration and washing. The number of attached cells was
determined by direct counting under a microscope (7 counts
per experimental setting).
Growth assay. Standard growth assays using crystal violet
were carried out over 5 days to determine whether the knock-
down of occludin changed the growth rate of MDA-MB-231
and MCF-7 breast cancer cells.
Immunofluorescent staining of human breast cancer cells.
For immunofluorescent staining, the cells were grown in 16-
well chamber slides (Lab-Tek International, Sussex, UK)
(30,000 cells/well) and incubated in a 37˚C/5% incubator for
a set period of time (0-24 h). After incubation, the culture
medium was aspirated, the wells were rinsed with balanced
salt solution (BSS) buffer and the cells were fixed in methanol
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for 20 min at -20˚C. After fixation, the cells were washed
twice using BSS buffer and permeabilised by the addition of
200 μl of 0.1% Triton X-100 (Sigma-Aldrich) detergent in
phosphate buffered solution for 5 min at room temperature.
The cells were rinsed twice with BSS buffer and 200 μl of
blocking buffer (10% horse serum in TBS) was added to
each well and the chamber slide was incubated for 40 min at
room temperature on a bench rocker. The wells were washed
once with wash buffer (3% horse serum in TBS buffer
containing 0.1% Tween-20) and 100 μl of primary antibodies
prepared in wash buffer were added to the appropriate wells.
The chamber slide was incubated on the rocker for a further
60 min at room temperature. The wells were washed twice
with TBS buffer (with 0.1% Tween-20) and the cells were
incubated in 100 μl of secondary antibodies (fluorescein
isothiocyanate or tetramethyl rhodamine iso-thiocyanate
conjugates; Sigma-Aldrich) (diluted in the same manner as
the primary antibodies) for 50 min. The chamber slide was
wrapped in foil to prevent light reaching the conjugate.
Finally, the wells were rinsed twice with wash buffer, once
in BSS buffer mounted with FluorSave™ (Calbiochem-
Novabiochem Ltd., Nottingham, UK) reagent and visualized
using an Olympus BX51 microscope with a Hamamatsu
(Welwyn Garden City, Herts, UK) Orca ER digital camera at
x100 magnification using an oil immersion lens at room
temperature (immersion oil by Fluka, Sigma-Aldrich). Images
were captured using AnalySIS Five Software (Olympus UK
Ltd. Essex, UK) and colourised using Adobe Photoshop CS2.
SDS-PAGE and Western blotting. Total cell lysates and tissues
were prepared as follows: The cells were pelleted or the tissue
was macerated and lysed in HCMF buffer plus 0.5% SDS,
0.5% Triton X-100, 2 mM CaCl2, 100 μg/ml phenylmethyl-
sulfonyl fluoride, 1 mg/ml leupeptin, 1 mg/ml aprotinin and
10 mM sodium orthovanadate for 40 min, sample buffer was
added and the protein boiled at 100˚C for 5 min before
clarification at 13,000 x g for 10 min. Equal amounts of
protein from each cell sample were added onto an 8% poly-
acrylamide gel. Following electrophoresis, the proteins were
blotted onto nitrocellulose sheets and blocked in 10% horse
serum for 60 min before probing with specific primary
antibodies, followed by peroxidase-conjugated secondary
antibody (1:2,000). The protein bands were visualised with
Supersignal West Dura Extended Duration Substrate chemi-
luminescence system (Perbio Science UK Ltd., Cramlington,
UK) and detected using a CCD UVIprochemi system (UVItec
Ltd., Cambridge, UK).
In vivo growth assay analyzing occludin knockdown breast
cancer cells. The in vivo tumour progression model was
adapted from similar previously described protocols (28,29).
Briefly, 2x106 cells in 100 μl were mixed in a 0.5 mg/ml
Matrigel suspension and subcutaneously injected into the left
and right flanks of 4-6-week-old athymic nude mice (CD-1;
Charles River Laboratories, Kent, England, UK) and allowed
to develop. The mice (n=5) were maintained in filter top units
and were weighed and the tumour size was measured weekly
using Vernier callipers under sterile conditions. Humane end-
points were i) mice which suffered 25% weight loss, and ii)
development of tumours exceeding 1 cm3 [subject to the
Schedule 1 method according to the United Kingdom Home
Office and the United Kingdom Coordinating Committee on
Cancer Research (UKCCCR) guidelines]. At the conclusion
of the experiment, the tumours were measured, the mice were
sacrificed as stated under Schedule 1 and the tumours were
removed and weighed. Tumour volume was determined using
the following formula: Tumour volume mm3 = 0.523 x width2
x length.
Tissue collection and preparation. Breast tissue samples (124
tumour and 33 matched background) (24), were collected and
immediately frozen in liquid nitrogen before processing. A
portion of each sample was for quantitative-PCR analysis,
another for immunohistochemical analysis and a third one for
routine histological examination. RNA was isolated from the
tissue samples using standard RNA-zol procedures. For RT-
PCR, cDNA was synthesized in a 20 μl reaction mixture using
1 μg RNA, as described in the protocol (ABgene Reverse
Transcription System, Surrey, UK).
The anonymised breast tissue samples were obtained
within the guidlines of the appropriate ethics committee (BFO
TAF Health Authority 01/4303 and 01/4046). Informed
patient consent was not applicable in this instance (as stated
in the Human Tissue Act 2004, UK).
Quantitative-PCR. The Q-PCR system used the Amplofluor™
Uniprimer™ system (Intergen Company Oxford, UK) and
Thermo-Start® (ABgene). Specific primer pairs for occludin
were designed by the authors using Beacon Designer software
(Biosoft International, Palo Alto, CA, USA) manufactured by
Invitrogen, each amplifying a region that spans at least 1
intron generating an ~100 base pair product from both the
control plasmid and cDNA. The PCR primers were: OCZF
GAATTCAAACCGAATCATTG and OCZR ACTGA
ACCTGACCGTACATGAAGAATTTCATCTTCTGG.
Using the iCycler iQ system (Bio-Rad), which incorporates a
gradient thermocycler and a 96-channel optical unit, the
plasmid standards and breast cancer cDNA were simul-
taneously assayed in duplicate reactions using a standard hot-
start Q-PCR master mix. Q-PCR conditions were as follows:
Enzyme activation at 95˚C for 12 min, 1 cycle, followed by
60 cycles of denaturing at 95˚C for 15 sec, annealing at 55˚C
for 40 sec, and then extension at 72˚C for 25 sec. Using
purified plasmids as internal standards, the level of cDNA
(copies/50 ng RNA) in the breast cancer samples was
calculated. Q-PCR for μ-actin was also performed on the
same samples, in order to correct any residual differences in
the initial level of RNA in the specimens (in addition to
spectrophotometry). The results were then normalized using
cytokeratin-19 levels in the same tissues. The products of
Q-PCR were verified on agarose gels (data not shown).
Immunohistochemistry. Cryostat sections of frozen tissue
were cut at 6 μm, placed on Super FrostPlus slides (LSL UK,
Rochdale, UK), air dried and fixed in a 50:50 solution of
alcohol:acetone. The sections were then air dried again and
stored at -20˚C until use. Immediately before the commence-
ment of immunostaining, the sections were washed in buffer
for 5 min and treated with horse serum for 20 min as a
blocking agent to non-specific binding. The sections were
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stained using occludin antibody (Insight Biotechnology,
Wembley, Cambridgeshire, UK). Negative controls were
used where necessary. Primary antibodies were used at 1:100
dilution for 60 min and then washed in buffer. The secondary
biotinylated antibody at 1:100 dilution (universal secondary,
Vectastain Elite ABC; Vector Laboratories Inc., Burlingham,
CA, USA) was added (in horse serum/buffer solution) for
30 min, followed by numerous washings. Avidin/biotin
complex was added for 30 min, again followed by washes.
Diaminobenzidine was used as a chromogen to visualize the
antibody/antigen complex. The sections were counterstained
in Mayer's hematoxylin for 1 min, dehydrated, cleared and
mounted in DPX. Following this, the sections were analyzed
for staining intensity as previously described (24,25).
Statistical analysis. Statistical analysis was performed by the
MINITAB version 13.32 (Minitab Inc. State College, PA,
USA) using a two-sample Student's t-test and the non-
parametric Mann-Whitney confidence interval and test or
Kruskal-Wallis, where appropriate. In addition, Microsoft
Excel Professional was used to calculate the correlation
coefficients and SPSS 12.01 for the survival curves.
Results
Expression of occludin in human breast tissues and cancer
cell lines. Overall, only 6/10 breast cancer cell lines expressed
full-length occludin (Fig. 2A). A closer comparison of an
invasive (MDA-MB-131, which did not express the full-
length) and a non-invasive (MCF-7, which expressed the
full-length) breast cancer cell line was carried out (Fig. 2B)
with the human endothelial cell line HECV as the positive
control. Both expressed the correct Ocr3 region, although
however, they also both expressed the truncated versions.
Only a faint signal was observed for the correct Ocr4 region
in the MCF-7 cells, which was not observed in the MDA-
MB-231 cells. Both however, expressed a larger version of
~500 bp, which was stronger in the case of the MDA-MB-
231 cells. This perhaps demonstrates why only a faint signal
was shown for MCF-7 but no signal was produced by the
MDA-MB-231 cells for the full-length version of occludin.
In a small set of human tumour and normal tissues from the
same patients, all of the 6 tumour tissues showed truncated
and/or variant signals for the N-terminal and first trans-
membrane loop of occludin (as amplified using the Ocr1 and
Ocr3 primer pairs). Four of these 6 tumour tissues did not
express the C-terminal region of occludin (as amplified
using the Ocr4 primer pairs) (Fig. 2C). However, paired back-
ground tissues showed similar expression profiles. Strong
methylation of the promoter was not observed (Fig. 2D) and
none of the breast tissues showed methylation of the occludin
promoter (data not shown). Western blotting demonstrated
the expression of variants of occludin when probed with 3
antibodies specific for the N-terminus, first membrane loop
and the C-terminus in the MDA-MB-231 and MCF-7 cells
(Fig. 2E). The N-terminus precipitated only the 82 kDa
form of occludin. The remaining 2 antibodies precipitated the
82 kDa form (only faintly with H-279) and also the 65 kDa
form, as expected. However, another form of ~70 kDa was
precipitated with these antibodies. This variant did not corre-
spond to the occludin signals for changes in the phospho-
rylation status of the protein, and thus it is anticipated that it
represents the true variant of occludin.
Knockdown of occludin in human breast cancer cells. The
knockdown of occludin expression in both the MDA-MB-231
and MCF-7 cells (MDA-MB-231ΔOcc and MCF-7ΔOcc) was
confirmed by Western blotting (Fig. 3A) and by immuno-
fluorescent staining (Fig. 3B). The absence of occludin could
clearly be observed compared to the wild-type (MDA-MB-
231WT and MCF-7WT) and the control plasmid cells (MDA-
MB-231Plas and MCF-7Plas) as almost the complete absence of
signal in the Western blots. The blot was carried out detecting
the N-terminus (82 kDa form). Immunofluorescent staining
showed the complete loss of occludin staining at both the
cell-cell junctions and in the cytoplasm (using the same anti-
body).
In vitro growth of occludin-knockdown human breast cancer
cells. Growth assays were performed over 5-day growth for
the knockdown cell lines and their controls. MDA-MB-231ΔOcc
showed no difference in growth patterns when compared to
the wild-type and the control plasmid groups (Fig. 4A). How-
ever, growth was elevated in the MCF-7ΔOcc cells compared
to the controls (Fig. 4B) at 2-3 days of growth (p=0.004 and
p=0.003 MCF-7WT and MCF-7Plas, respectively) but this was
abrogated within 5 days, with no noticeable difference in
growth rate.
In vitro invasion of occludin-knockdown human breast cancer
cells. Invasion assays were carried out to ascertain any effect
of the occludin-knockdown in both human breast cancer cell
lines. MDA-MB-231ΔOcc showed increased invasion (RDU
0.228±0.009, n=10) compared to both the wild-type and
control plasmid cells (MDA-MB-231WT 0.205±0.01, p=0.019
and MDA-MB-231Plas 0.207±0.01, p=0.038) (Fig. 4C). Treat-
ment with HGF (25 ng/ml) elevated this increased invasion
(MDA-MB-231ΔOcc 0.32±0.005 vs. MDA-MB-231WT
0.31±0.004, p=0.27 and vs. MDA-MB-231Plas 0.27±0.005,
p<0.0001). Even though MCF-7 cells are not highly invasive,
the knockdown of occludin increased the invasiveness of
these cells (MCF-7ΔOcc 0.055±0.0005 vs. MCF-7WT
0.05±0.009, p=0.27 and vs. MCF-7Plas 0.049±0.002,
p<0.0001) (Fig. 4D). HGF (25 ng/ml) magnified this increase
in invasiveness (MCF-7ΔOcc 0.057±0.0019 vs. MCF-7WT
0.054±0.002, p=0.04 and vs. MCF-7Plas 0.052±0.001,
p=0.003). These results were expected, as we have already
demonstrated that HGF reduces occludin in these cell lines
(23). It is evident that the knockdown of occludin produces a
similar physiological effect as the reduced occludin
expression.
In vitro adhesion of occludin knockdown human breast cancer
cells. The knockdown of occludin in the MDA-MB-231 cells
resulted in a remarkable decrease in the adhesiveness to the
basement membrane (Fig. 4E) when compared to both the
wild-type and plasmid control cells (MDA-MB-231ΔOcc
0.095±0.016 RDU, n=10; MDA-MB-231WT 0.267±0.004,
p=0.0002; MDA-MB-231Plas 0.268±0.027, p=0.002). HGF
(25 ng/ml) did not cause great change in the knockdown
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cells (MDA-MB-231ΔOcc 0.0109±0.013; MDA-MB-231WT
0.285±0.014, p=0.0009; MDA-MB-231Plas 0.286±0.017,
p=0.002). Similarly, the occludin knockdown also reduced
the adhesion of the MCF-7 cells (MCF-7ΔOcc 0.039±0.008
vs. MCF-7WT 0.052±0.006, p=0.18 and vs. MCF-7Plas
0.049±0.002, p=0.17) but this did not reach significance
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Figure 2. Expression of occludin variants in human breast cancer cell lines and paired human breast tumour/background tissues. (A) Presence or absence of
the full occludin transcript in human breast cancer cell lines. (B) A comparison of the differences in expression of variants within the occludin transcript of
MDA-MB-231 and MCF-7 human breast cancer cells. Amplification of 3 regions within the occludin transcript (Oc1, Oc3, Oc4) was carried out, with HECV
cells as the controls. (C) Amplification of the same 3 regions of occludin in paired tumour/background tissues. (D) Methylation status of the occludin
promoter in selected human breast cancer cell lines (HECV as the control). (E) Immunoprecipitation of occludin from MDA-MB-231 and MCF-7 cell lines
using 3 antibodies representing 3 different epitopes of occludin (mapping to 3 regions).
Figure 3. Successful knockdown of occludin in MDA-MB-231 and MCF-7 human breast cancer cell lines. (A) Western blots showing the absence of the
occludin protein in MDA-MB-231 (top) and in MCF-7 knockdown cells (bottom). Actin was used as the loading control. (B) Immunofluorescence showing
the absence of occludin in the knockdown cells (ΔOcc).
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Figure 4. Effect of occludin knockdown on the behaviour of human breast cancer cell lines. In vitro growth assay of (A) MDA-MB-231 and (B) MCF-7 cells
comparing ΔOcc with the wild-type (WT) and plasmid control (Plas). Invasion of (C) MDA-MB-231 and (D) MCF-7 cells, as above, using HGF (25 ng/ml) to
promote invasive behaviour. Adhesion to basement membrane of (E) MDA-MB-231 and (F) MCF-7 cells, as above. (G) Change in TER of MDA-MB-231
knockdown cells and (H) change in PCP of the same cells. (I) In vivo growth of knockdown MDA-MB-231 cells.
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(Fig. 4F). This remained true even after the application of
HGF (25 ng/ml), which in these cells reduced adhesiveness
(MCF-7ΔOcc 0.036±0.007 vs. MCF-7WT 0.048±0.004, p=0.14
and vs. MCF-7Plas 0.0469± 0.001, p=0.13).
Changes in TJ function of occludin knockdown cells. MDA-
MB-231 cells were then further assessed for the effect of
occludin knockdown on TJ functionality, in the same manner
as using changes in TER and in paracellular permeability
(PCP). The knockdown of occludin resulted in a marked
reduction in TER over 2-h treatment with HGF (25 ng/ml)
compared to the control cells [changes in TER (ohms)
within 2 h: MDA-MB-231ΔOcc -116.33±1.74; MDA-MB-
231WT -40.3±4.44, p=0.02; MDA-MB-231Plas -43±27,
p=0.004] (Fig. 4G). This was reflected by a concurrent
increase in PCP over the same period of time [changes in
PCP (RFU) within 2 h: MDA-MB-231ΔOcc 520±100; MDA-
MB-231WT 250±10, p=0.04; MDA-MB-231Plas 360±100,
p=0.043] (Fig. 4H).
In vivo tumour growth of occludin knockdown cells. After 27
days of growth, the occludin knockdown did not significantly
affect the growth rate of the MDA-MB-231 human breast
cancer cells in the athymic nude mouse model (final tumour
volume mm3: MDA-MB-231ΔOcc 263.028±108.657 vs. MDA-
MB-231WT 244.45±98.28, p=0.92) (Fig. 4I). This reflects the
in vitro growth of these cells.
Distribution and expression of occludin in tumour and
background cancer tissues. We carried out an immuno-
histological study to assess the location, distribution and the
degree of staining of occludin using 10 pairs of matched
samples (tumour and background tissue). In normal mammary
tissues, occludin appeared as strong staining in the epithelial
and endothelial cell lining vessels (black arrows) and ducts
with no staining of cells in the stroma (Fig. 5A, background,
increasing magnification). The staining for occludin within
the tumour sections was, however, greatly decreased in both
the cancer and surrounding cells, as well as in their lining
vessels (Fig. 5A, tumour, increasing magnification). This is
illustrated by the transition seen between the tumour and the
associated normal/background tissue as shown in Fig. 5A.
Moreover, the staining distribution within the cells from the
background tissues was correctly located at the junctional
regions of the cells, plainly at the TJ (black arrows). No such
distribution was observed in the cells from the tumour
sections, where little staining even in the cytoplasm was
observable. Thus, the overall staining intensity was reduced
in the tumour cells, compared to the normal/ background
sections, as was assessed using image analysis (tumour mean
±SD 57.6±43.91 vs. background 186.53±16.98, p<0.00001)
(Fig. 5B).
When the occludin expression was examined at the mRNA
level using quantitative PCR, the levels were not significantly
different between the tumour and background tissue (tumour
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Figure 5. (A) Representative tissue sections stained to show the presence of occludin (background) and the absence of occludin (tumour) in human breast
cancer, x100 magnification. The negative and positive controls for the staining are also shown (bottom). (B) Densitometry of the sections to show the
significant reduction of occludin staining in the tumour sections (n=15).
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mean ±SE 315.2±70.9 vs. background 184.6±62.1, p=0.17).
There was no significant difference in the expression
between the node-positive and the node-negative tumours
(node-positive 263.4±78.4 vs. node-negative 293.9±97.2,
p=0.81).
Correlation of occludin expression with prognosis and
staging. The Nottingham Prognostic Index (NPI) was used as
the parameter to assess the prognosis of the patients, in that
patients with an NPI value of <3.4 (NPI-1) were regarded to
have good prognosis, those with a value of 3.4-5.4 (NPI-2)
moderate prognosis, and those with a value of NPI >5.4
(NPI-3) poor prognosis. The formula for NPI being: NPI =
[0.2 x size cm] + grade (1-3) + nodal status (1-3). There was
a stepwise decrease in the occludin expression with poor
prognosis (Fig. 6A), i.e. NPI-2-3 tumours (NPI >3.4),
although this did not reach significance (NPI-1 293.9±97.2;
NPI-2 279±103; NPI-3 224±103; p>0.13). The levels of the
molecules were also analyzed against the grade of tumours
and also showed a decrease in occludin expression in grade-2
and -3 tumours, but this did not reach significance (grade-1,
529±228; grade-2, 214.2±90; grade-3, 319±108; p>0.21)
(Fig. 6B). No trend was observed with the TNM tumour
status.
Correlation with ER status indicated that occludin was
reduced in the ER-positive tumours (ER-negative 384±115
vs. ER-positive 217.3±63.2, p=0.21) with a reduction also in
the expression in the ERß-negative vs. the ERß-positive
tumours (337.1±92.1 vs. 256±118, respectively, p=0.59).
Interestingly, the occludin expression was lower in lobular
cancers compared to the ductal type (lobular, 236±125;
ductal, 345.4±88.8) although significance was not reached
(p=0.37). There was an increased expression of occludin in
ductal cancers compared to other types (ductal, 345.4±88.8;
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Figure 6. Q-PCR showing the changes in the copy number of occludin in patient tissues (transcript copy number/50 ng/ml RNA). (A) The levels of occludin
decreased with increasing NPI status. (B) Occludin is reduced in grade 2-3 tumours. (C) The expression of occludin was higher in ductal carcinoma compared
to other types. (D) In the breast tissue cohort used, occludin was reduced with increasing grade in the ductal tumours. (E) Patients who had metastatic disease
had significantly reduced levels of occludin (p=0.024). (F) Survival curve of patients in the current cohort.
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others, 131.2±96.8) which approached significance (p=0.09)
(Fig. 6C). Moreover, there was a striking reduction in occludin
expression in higher grade ductal tumours (Fig. 6D).
Expression of occludin and clinical outcome following 10-
year follow-up. Fig. 6E shows data comparing patients who
remained alive and well to those who had metastatic disease
after a median follow-up of 120 months. Those patients with
metastatic disease had significantly reduced levels of occludin
expression compared to those without disease (metastatic
disease, 93.1±31.7 vs. disease-free, 331.3±98.4, p=0.024).
Patients who had local recurrences also showed decreased
occludin expression when compared to those who remained
disease-free (local recurrence, 290±203, p=0.86). Patients
who died of breast cancer did not have significantly reduced
levels of occludin compared to the patients who remained
alive and well (328.9±87.6, p=0.99). Overall poor outcomes
were reduced compared to those who remained alive and well
(269.3±64.7, p=0.6). These data show that reduced occludin
expression is associated with poor prognosis and outcome in
patients with metastatic disease.
Survival curves (over 120 months) showed that reduced
occludin transcript levels were associated with poor overall
survival in patients with breast cancer as was analysed using
the Cox-Proportion-Hazardous test (p=0.2643), Fig. 6F.
Discussion
This study shows that occludin is aberrantly expressed in
both human breast cancer cell lines and in human breast
tumour tissues, due to pre- and possibly post-translational
events. The knockdown of occludin in human breast cancer
cell lines leads to the reduced TJ function in MDA-MB-231
and MCF-7 cells and the reduced ability to adhere to the
basement membrane. In vitro and in vivo growth was,
however, not affected. Moreover, the expression of occludin
was significantly reduced in human breast tumour tissues
when compared to background ones, as revealed by
immunohistochemistry, with Q-PCR analysis revealing that
the loss of occludin was significantly correlated with patients
who had died of metastatic disease.
Although occludin was one of the first TJ proteins
discovered, its function in the TJ is poorly defined (30). The
suppression of occludin is associated with a decrease in the
claudin-1 and -7 and an increase in the claudin-3 and -4
expression. It has been indicated that occludin transduces
external (apoptotic cells) and intra-membrane (rapid choles-
terol depletion) signals via a Rho signalling pathway that, in
turn, elicits the re-organization of the actin cytoskeleton.
Impaired signalling in the absence of occludin can also alter
the dynamic behaviour of TJ strands, as reflected by the
increase in permeability to large organic cations, although
however, the permeability of ion pores formed by claudins, is
less affected.
This study has shown that there were a few variants of
occludin observable in the human breast tissues and human
cell lines investigated. The human breast tissues showed
aberrant/truncated forms of occludin, with a significant
number (4/6) not expressing the C-terminal. Overall, only 3
cell lines expressed the full-length version of occludin. No
methylation of the occludin promoter was observed, and
therefore we can conclude that occludin undergoes a number
of translational modifications. We also decided to investigate
the human breast cancer cell lines MDA-MB-231 and
MCF-7, as we had previously observed aberrant expression
of occludin by these cells (23). Immuno-precipitation using 3
occludin antibodies and 3 different epitopes revealed that the
N-terminus was able to pull out only the 82 kDa form of
occludin, but that both the H-279 and C-terminus epitopes
pulled out 2 forms of occludin protein in both cell lines, the
82 kDa form and another truncated form of ~70 kDa which
corresponds to the form we had previously observed (24).
This form does not correspond to known phosphorylated
forms of the protein and therefore demonstrates that the
occludin protein in these cell lines is truncated, possibly due
to the loss of the N-terminus.
This is not the first time that alternate forms of occludin
have been observed. An alternatively spliced form of occludin,
occludin 1B was identified in MDCK cells and cultured T84
human colon cancer cells (31). There are 2 gene products, the
larger, predominant product corresponding to the canonical
occludin (TM4+), whilst the smaller product exhibits a 162 bp
deletion encoding the entire TM4 and immediate C-terminal
flanking region (TM4-) (32). The deleted section corresponds
to exon 4, suggesting that TM4- is an alternatively spliced
isoform. TM4- was also found in monkey epithelial cells, but
not in murine or canine ones. The staining of occludin in
Caco-2 cells with a C-terminal occludin antibody revealed
weak, discontinuous staining restricted to the periphery of
subconfluent islands. A weak band at 58 kDa (smaller than
the predominant band at 65 kDa) corresponded to the
predicted mass after blotting. The authors suggest that the
TM4- isoform is up-regulated in the subconfluent cells, and
that it is translated at low levels in specific conditions and
could contribute to the regulation of occludin function, i.e. if
occludin has no C-terminus, it cannot bind to ZO-1. Such
alternatively spliced forms could therefore explain the variants
found in our study, particularly the loss of the N-teminus
region (for correct assembly within the TJ) and the loss or
truncation of the C-terminal region. This is essential for the
correct intracellular trafficking of occludin to the membrane
and binding to the GUK sites of ZO-1 (33). Moreover, the
loss of the first transmembrane region indicates a reason as to
why, even though occludin is present, it does not contribute
to the function of the TJ structure. Zeng et al (34) observed
that in human cervical cells, 17ß-estradiol modulated the
expression of the 65 kDa occludin form at low concentrations
(1-10 nM), but that at higher concentrations (100 nM) it
induced an expression of a 50 kDa form of occludin that was
the result of the post-translational up-regulation of the
occludin turnover, including synthesis and degradation. This
kind of modification is clearly not a contributory factor in
our study.
It has also been shown that in contrast to earlier studies,
the complete or partial truncation of the C-terminal of occludin
alone, does not prevent the correct targeting of occludin to
the TJ in epithelial cells, and that TM4 deletions were most
important for correct targeting, leading to occludin that was
retained intracellularly (35). It is becoming increasingly clear
that occludin is a complex and multi-functional protein. The
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loss or truncation of occludin also has repercussions on other
proteins in epithelial cells. It has also been shown that
occludin has a potent inhibitory effect on Raf1-mediated
tumourigenesis in epithelial derived cancers, with the second
extracellular loop being critical for this behaviour (36).
We also considered the effect of occludin knockdown in
the human breast cancer cell lines MDA-MB-231 and MCF-7.
The successful knockdown of occludin resulted in cells with
a dramatically altered phenotype with regards to changes in
adherence to the basement membrane and in the loss of TER
and increased PCP in both cell lines. This indicates that the
loss of occludin leads to a more aggressive phenotype in
these cells, particularly the phenotype of MCF-7 cells, which
is usually the less aggressive cell line. Interestingly, there
was little change in the in vitro and in vivo growth rates of
the MDA-MB-231 occludin knockdown. However, the
MCF-7 knockdown showed an increased in vitro growth rate,
commensurate with an increased aggressive phenotype.
Previous studies have highlighted the results of occludin
overexpression (37,38). The forced expression of occludin in
MCF-7, murine breast and melanoma cancer cell lines
resulted in cells with an enhanced sensitivity to apoptogenic
factors, therefore leading to the inhibition of tumourigenicity
of transfected cells and demonstrating that the epigenetic
silencing of occludin results in the acquisition of apoptotic
resistance, identifying occludin as a likely candidate for a
tumour-suppressor gene in certain tumour types (37). Osanai
et al (38) demonstrated that the overexpression of occludin
induced anoikis and promoted oxidative stress-induced
premature senescence in breast carcinoma cells, accompanied
by the up-regulation of negative cell cycle regulators, and
thereby suggesting that the loss of occludin expression could
be involved in the senescence-escape program during breast
cancer progression.
Certain studies have suggested that some of the cell
adhesion and cytoskeletal proteins could subserve an
additional and important function, namely the suppression of
the malignant phenotype of cells in tumourigenesis (39).
Whilst the barrier and fence functions of TJs have been well
appreciated in the past, it was not till later that the concept of
the TJ as a complex, multiprotein structure with roles in other
cellular processes such as cell polarity, proliferation and
differentiation, was recognised (40). Moreover, it is becoming
increasingly clear that the development of human cancer is
frequently associated with the failure of epithelial cells to
form TJs and establish correct apicobasal polarity (41).
Our study examined the expression of occludin in human
breast tissues. The occludin expression was significantly
reduced as was observed from the immunohistochemical
staining of the paired tumour/background tissues. Moreover,
Q-PCR analysis revealed that the loss of occludin was
associated with the increasing aggressiveness of tumours (as
ascertained using NPI scores and tumour grade) and with
tumour type. The loss of occludin was significantly associated
with death from metastatic disease in patients with breast
cancer. Although the loss of occludin has been described in
other cancer types (42-47), there has been no comprehensive
study on human breast cancer. Thus, this is the first study
demonstrating that the reduced occludin expression can be
linked to the disease process in human breast cancer. The
association of occludin with metastatic disease in human
breast cancer patients is an area that deserves further
scrutiny.
In conclusion, we demonstrate here for the first time that
occludin is differentially expressed in breast tumour tissues
and in human breast cancer cell lines. The changes in occludin
message indicate that variants are expressed in tumour tissue.
The loss of/truncation of the N-terminus indicates the reduced
assembly of the TJ structure and the reduced maintenance of
the barrier function. The loss of C-terminal expression
suggests the reduced intracellular trafficking of occludin to
the basolateral membrane and binding to ZO-1, resulting in
reduced TJ anchoring, assembly and cell-cell adhesion. This
has clear repercussions as to the importance of occludin in
maintaining TJ integrity in breast tissues. Such inappropriate
expression could play a part in breast cancer development.
The knockdown of endogenous occludin in human breast
cancer cells leads to the profoundly reduced junctional
integrity, loss of tightness and increased invasive potential of
these cells. Moreover, the loss of occludin expression is
associated with metastatic disease in patients with breast
cancer. It is becoming increasingly clear that occludin is
essential for the correct functioning of the TJ in human breast
epithelial cells.
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